Companies · Biotech

LEAH LabsWinter 2019Active

Minneapolis · MN, USA · Biotech · founded 2018 · http://www.leahlabs.com

Diligence memoA one-page analyst read on LEAH Labs — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 34%
Sector rank · raised
Latest stage · inferred

LEAH Labs: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Where it sits in Biotech

LEAH Labs is one of 233 Biotech companies tracked from Minneapolis, MN, USA, on record since 2018. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Living therapies for pets first, and their people next

LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective "full stack" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.

CRISPRCell TherapyDrug discoverybiotech
Find LEAH Labs online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$7.8M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$56.1M

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

LEAH Labs is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
10x ScienceBiotechsame sector
1849 bioBiotechsame sector
1910Biotechsame sector
20nBiotechsame sector
54Gene, Inc.BiotechSeries B$48.3M$598.4Msame sector
Abacus Bioscience Inc.BiotechSeries A$4.4M$46.6Msame sector
Abalone BioBiotechsame sector
Acoustic Wave Cell Therapy, Inc.BiotechSeries A$20.5M$84.9Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Animal Cell Therapies, Inc.BiotechnologySeries A$202.0M77%
Humane Genomics
A platform to make artificial viruses as cancer therapeutics.
Biotech76%
Modulari-T
We teach your immune system to attack and cure cancer
Biotech75%
ImmunityBio, Inc.
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
BiotechnologyGrowth/Late$7.8B74%
Guardian Bio
Dendritic cell-based platform for cancer therapy
Biotech74%
Curelab Veterinary, Inc.BiotechnologySeed$33.7M74%
Ditto Biosciences
Evolutionary intelligence for autoimmune disease
Biotech73%
CellChorus
The dynamic single-cell analysis company
Biotech72%
Frequently asked
What does LEAH Labs do and where is it based?
LEAH Labs operates in the Biotech sector, based in Minneapolis, MN, USA. Living therapies for pets first, and their people next
Explore related

See where LEAH Labs sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at LEAH Labs, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.